Wellington Management Group LLP Has $3.76 Billion Position in Johnson & Johnson $JNJ

Wellington Management Group LLP cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,645,961 shares of the company’s stock after selling 1,710,611 shares during the quarter. Johnson & Johnson comprises 0.7% of Wellington Management Group LLP’s portfolio, making the stock its 21st biggest holding. Wellington Management Group LLP owned 0.94% of Johnson & Johnson worth $3,755,606,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in JNJ. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after buying an additional 1,170,120 shares in the last quarter. Northern Trust Corp grew its holdings in Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after buying an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Johnson & Johnson by 3.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after acquiring an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Johnson & Johnson by 2.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after acquiring an additional 448,666 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on JNJ shares. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. UBS Group upped their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Price Performance

Shares of JNJ opened at $176.76 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $177.27. The business has a 50-day simple moving average of $161.28 and a two-hundred day simple moving average of $158.43. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $425.70 billion, a PE ratio of 18.90, a PEG ratio of 2.25 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.